Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
VERA | US
-0.10
-0.26%
Healthcare
Biotechnology
30/06/2024
09/03/2026
38.97
38.56
39.60
38.00
Vera Therapeutics Inc. a clinical stage biotechnology company focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868 a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair Inc. and changed its name to Vera Therapeutics Inc. in April 2020. Vera Therapeutics Inc. was incorporated in 2016 and is headquartered in Brisbane California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
27.3%1 month
30.0%3 months
50.0%6 months
62.2%-
-
6.88
0.16
0.13
-3.60
-
-
-90.73M
2.14B
2.14B
-
-
-
-
-46.05
9.65
15.83
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
6.29
Range1M
6.99
Range3M
18.08
Rel. volume
1.21
Price X volume
49.71M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| BEAM THERAPEUTICS INC. | BEAM | Biotechnology | 27.62 | 2.28B | 4.07% | n/a | 19.35% |
| VIRIDIAN THERAPEUTICS ORS INC | VRDN | Biotechnology | 29.65 | 2.26B | 4.62% | n/a | 3.96% |
| Travere Therapeutics Inc. | TVTX | Biotechnology | 28.98 | 2.22B | 6.39% | n/a | 2662.08% |
| Adeptus Health Inc | ADPT | Biotechnology | 14.95 | 2.20B | 0.61% | n/a | 93.65% |
| Apollomics Inc. Class A Ordinary Shares | APLM | Biotechnology | 20.01 | 2.20B | -0.25% | n/a | 21.43% |
| PROK | PROK | Biotechnology | 2.39 | 2.20B | 3.91% | n/a | -0.69% |
| Galapagos NV | GLPG | Biotechnology | 33.06 | 2.18B | 0.43% | 59.15 | 0.00% |
| Arcus Biosciences Inc | RCUS | Biotechnology | 23.43 | 2.14B | 5.97% | n/a | 1.73% |
| Day One Biopharmaceuticals Inc. Common Stock | DAWN | Biotechnology | 21.33 | 2.10B | 0.61% | n/a | 0.06% |
| Ultragenyx Pharmaceutical Inc | RARE | Biotechnology | 22.61 | 2.08B | 6.40% | n/a | 214.27% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| HNI Corporation | HNI | Building Products & Equipment | 41.37 | 1.95B | -0.17% | 22.12 | 76.47% |
| Pitney Bowes Inc | PBI | Building Products & Equipment | 10.67 | 1.92B | 0.85% | n/a | -571.93% |
| ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 14.07 | 1.41B | 1.22% | n/a | 19.46% |
| Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 36.22 | 1.14B | 1.06% | 51.60 | 88.92% |
| Winnebago Industries Inc | WGO | Recreational Vehicles | 35.25 | 1.02B | -2.87% | 22.53 | 56.33% |
| Janus International Group Inc. | JBI | Building Products & Equipment | 5.39 | 783.29M | 1.89% | 11.62 | 116.21% |
| Latham Group Inc. | SWIM | Building Products & Equipment | 6.31 | 729.29M | 0.16% | 65.18 | 77.00% |
| Fox Factory Holding Corp | FOXF | Recreational Vehicles | 16.37 | 682.35M | 0.37% | 42.05 | 64.69% |
| Ennis Inc | EBF | Building Products & Equipment | 21.16 | 550.24M | -0.70% | 13.28 | 2.28% |
| Malibu Boats Inc | MBUU | Recreational Vehicles | 25.67 | 513.16M | -0.39% | n/a | 1.50% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.60 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 6.88 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 49.96 | 72.80 | Lower Risk |
| Debt to Equity | 0.16 | -1.23 | Expensive |
| Debt to Assets | 0.13 | 0.25 | Cheaper |
| Market Cap | 2.14B | 3.66B | Emerging |